Drug Profile
Research programme: linear DNA based coronavirus vaccines - LineaRx/Takis
Alternative Names: 2019-nCoV coronavirus vaccine - LineaRx/Takis; LineaDNA™; Linear DNA based coronavirus vaccines - Takis/LineaRx; LinearDNA™ COVID-19 Vaccine-LinearRx/TakisLatest Information Update: 22 Jul 2020
Price :
$50
*
At a glance
- Originator LineaRx; Takis
- Class COVID-19 vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 17 Jul 2020 Positive immunogenicity data from preclinical studies in COVID-2019 infections released by Applied DNA Sciences and Takis
- 17 Jul 2020 Applied DNA Sciences and Takis Biotech plans a first in human clinical trials in December 2020
- 08 Jun 2020 Applied DNA Sciences and Takis plan additional toxicology studies with third-party (assuming positive results from ongoing dose-response studies) for COVID-2019 infections (Prevention) (Parenteral)